肺热咳喘方联合常规疗法治疗社区获得性肺炎痰热壅肺证临床研究
CSTR:
作者:
中图分类号:

R563.1

基金项目:

浙江省中医药科技计划项目(2021ZB304)


Clinical Study on Feire Kechuan Prescription Combined with Conventional Therapy for Community-Acquired Pneumonia with Phlegm-Heat Obstructing the Lung Syndrome
Author:
  • 摘要
  • | |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • | |
  • 文章评论
    摘要:

    目的:观察肺热咳喘方联合常规疗法治疗社区获得性肺炎痰热壅肺证的疗效。方法:选取123 例 痰热壅肺证社区获得性肺炎患者,按随机数字表法分为对照组60 例及联合组63 例。对照组采用常规西药治 疗,联合组采用肺热咳喘方联合常规西药治疗,2 组均治疗2 周。观察2 组临床疗效、影像学检查结果、不良 反应发生情况及临床症状消退时间,比较2 组治疗前后中医证候积分、血清C-反应蛋白(CRP)、降钙素 原(PCT)、白细胞计数(WBC) 水平的变化。结果:治疗后,2 组中医证候积分主症、次症、总分均较治疗 前下降(P<0.05),联合组中医证候积分主症、次症、总分均低于对照组(P<0.05)。治疗后,联合组退热、 咳嗽消退、咳痰消退及肺部啰音消退时间均短于对照组,差异均有统计学意义(P<0.05)。治疗后,2 组 CRP、PCT、WBC 水平均较治疗前下降(P<0.05),联合组上述3 项水平均低于对照组(P<0.05)。治疗后, 联合组影像学吸收率为95.24%,对照组为81.67%,2 组比较,差异有统计学意义(P<0.05)。联合组临床疗 效总有效率为95.24%,对照组为81.67%,2 组比较,差异有统计学意义(P<0.05)。联合组不良反应发生率 为6.35%,对照组不良反应发生率为8.33%,2 组比较,差异无统计学意义(P>0.05)。结论:肺热咳喘方联 合现代医学治疗社区获得性肺炎痰热壅肺证能明显缓解症状,降低炎症水平,临床疗效显著,且安全性良好。

    Abstract:

    Abstract: Objective: To observe the curative effect of Feire Kechuan Prescription combined with conventional therapy for community-acquired pneumonia with phlegm-heat obstructing the lung syndrome. Methods:A total of 123 cases of patients with community-acquired pneumonia with phlegmheat obstructing the lung syndrome were selected and divided into the control group and the combination group according to the random number table method,with 60 and 63 cases in each group,respectively. The control group was treated with conventional western medicine treatment,and the combination group was treated with Feire Kechuan Prescription combined with conventional western medicine therapy. Both groups were treated for 2 weeks. Clinical effects, imaging findings, the incidence of adverse reactions, and the remission time of clinical symptoms were observed in the two groups. Traditional Chinese medicine (TCM) syndrome scores and the levels of C-reactive protein (CRP), procalcitonin (PCT), and white blood cell count (WBC) in serum were compared between the two groups before and after treatment. Results: After treatment, the scores of main symptoms and secondary symptoms, and the total scores of TCM syndrome scores in the two groups were decreased when compared with those before treatment (P<0.05), the scores of main symptoms and secondary symptoms,and the total scores of TCM syndrome scores in the combination group were lower than those in the control group (P<0.05). After treatment,the remission time of fever,cough,expectoration,and lung rales in the combination group was shorter than that in the control group,differences being significant (P<0.05). After treatment,the levels of CRP,PCT and WBC in the two groups were decreased when compared with those before treatment (P<0.05), and the above three levels in the combination group were lower than those in the control group (P<0.05). After treatment, the imaging absorption rate was 95.24% in the combination group and 81.67% in the control group, the difference being significant (P<0.05). The total clinical effective rate was 95.24% in the combination group and 81.67% in the control group, the difference being significant (P<0.05). The incidence of adverse reactions was 6.35% in the combination group and 8.33% in the control group,there being no significance in the difference (P>0.05). Conclusion:In the treatment of community-acquired pneumonia with phlegmheat obstructing the lung syndrome, Feire Kechuan Prescription combined with modern medicine can significantly relieve symptoms and reduce the levels of inflammation,with obvious clinical effects and good safety.

    参考文献
    相似文献
    引证文献
引用本文

何薇,李慧娇,李国华,王一萍,尤志新.肺热咳喘方联合常规疗法治疗社区获得性肺炎痰热壅肺证临床研究[J].新中医,2024,56(1):61-66

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 在线发布日期: 2024-01-16
文章二维码